

## Pfizer – Recall of Nurtec<sup>®</sup> ODT (rimegepant)

- On March 16, 2023, [Pfizer announced](#) a consumer-level recall of [Nurtec ODT \(rimegepant\)](#) 75 mg orally disintegrating tablets sold in cartons containing one blister card of 8 tablets because the tablets are in a non-child resistant blister card.
  - For new or refill prescriptions, pharmacists will place Nurtec ODT blister packages into vials with child-resistant lids when filling patient prescriptions.
- The recalled Nurtec ODT was sold at pharmacies nationwide between December 2021 and March 2023.

Product Description	NDC#	Expiration Date
Nurtec ODT (rimegepant) 75mg 8-unit dose blister pack	72618-3000-2	All dates through 6/2026

- Nurtec ODT is indicated for the acute treatment of migraine with or without aura in adults and for the preventive treatment of episodic migraine in adults.
- Nurtec ODT packaging does not meet the child-resistant packaging requirements for oral prescription drugs, potentially posing a risk of harm if the contents are swallowed by young children.
- Patients who are currently using the recalled Nurtec ODT should continue to use Nurtec ODT as prescribed by their healthcare provider. Patients should store Nurtec ODT in a safe location, out of the reach and sight of children. Patients should contact Pfizer to request a child-resistant pouch in which to store the medication.
- Anyone with an existing inventory of the recalled product should place Nurtec ODT blister packages into vials with child-resistant lids when filling patient prescriptions.
- Contact Pfizer by phone at **1-800-879-3477** or by e-mail at [www.Nurtec.com/PackagingUpdate](http://www.Nurtec.com/PackagingUpdate) or [www.Nurtec.com](http://www.Nurtec.com) for questions regarding this recall.